

Save the Date and Join us in Burlington!

SCOPE of Pain Half-Day Meeting | Saturday, May 10, 2014 | 8:30am-1:30pm Sheraton Burlington Hotel | Burlington, VT

What is SCOPE of Pain?

SCOPE of Pain is designed to help you safely and effectively manage patients with chronic pain, when appropriate, with opioid analgesics. The Burlington half-day meeting includes essential clinical content on opioid prescribing as well as state-specific information, including a policy and resource panel with representatives from State agencies.

SCOPE of Pain Vermont is sponsored by Boston University School of Medicine. National collaborators include the Council of Medical Specialty Societies and the Federation of State Medical Boards.

Why offer this training?

The FDA has mandated manufacturers of extended release/long-acting (ER/LA) opioid analgesics, as part of a comprehensive Risk Evaluation and Mitigation Strategy (REMS), to make available comprehensive prescriber education in the safe use of these medications. Our training is based on the FDA curriculum known as the Blueprint for Prescriber Education for Extended Release and Long-Acting Opioid (ER/LA) Analgesics. Our curriculum covers all aspects of this blueprint and more to provide a comprehensive educational program.

Who is this for?

Physicians, nurse practitioners, physician assistants, dentists, optometrists, podiatrists, and pharmacists

Educational Objectives:

At the completion of this education activity, you should be able to:

- Employ appropriate assessment, monitoring and documentation strategies to meet best practice standards and medico-legal requirements when treating patients with chronic opioid therapy (COT)
- Apply a practical framework for decision-making on the initiation, dosage modification, and discontinuation of opioid analgesics in the treatment of chronic pain
- Employ consistent practice tools to adequately assess risk in patients being considered for COT and to effectively manage COT
- Confidently counsel patients and caregivers about the safe use of opioid medications and communicate about the need for close monitoring
- Effectively communicate with patients whom you suspect may be misusing opioid analgesics
- Demonstrate increased understanding of general- and product-specific information of ER/LA opioid analgesics

Tuition: \$25

For more information and to register, visit www.scopeofpain.com

Accreditation

Course Director

Daniel P. Alford, MD, MPH, FACP, FASAM, Boston University School of Medicine

Physicians

This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of Boston University School of Medicine. Boston University School of Medicine is accredited by the ACCME to provide continuing medical education for physicians.

Boston University School of Medicine designates this live activity for a maximum of **5 AMA PRA Category 1 Credits™**. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurses

Continuing Nursing Education Provider Unit, Boston University School of Medicine is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.

CNE Contact Hours: 5

AAFP

This live series activity, SCOPE of Pain: Safe and Competent Opioid Prescribing Education, from May 18, 2013 - May 17, 2014, has been reviewed and is acceptable for **3 Prescribed Credits** by the American Academy of Family Physicians. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure of Support

Our program is funded by an independent educational grant awarded by the manufacturers of extended-release (ER) and longacting (LA) opioid analgesics, collectively known as the Risk Evaluation and Mitigation Strategy (REMS) Program Companies, or RPC. This activity is intended to be fully-compliant with the ER/LA Opioid Analgesic REMS education requirements issued by the U.S. Food & Drug Administration (FDA).